PRAME-targeting TCR cell therapy racing a Phase 3 enrollment clock against a burn rate that consumed €113M in six months

Immatics is a clinical-stage biopharmaceutical company developing a cell therapy for melanoma that has not yet been approved.

Anzu-cel (IMA203) is a PRAME-directed TCR-engineered T cell therapy for checkpoint inhibitor-failed metastatic melanoma, backed by RMAT designation and compelling Phase 1b response data. The thesis resolves on whether Phase 3 SUPRAME delivers a survival benefit sufficient for full approval, with Iovance's approved TIL therapy lifileucel competing directly for the same post-checkpoint patient pool. Cash of €232M against a €51M quarterly burn funds roughly four to five quarters, creating a financing dependency before Phase 3 data mature.